Restriction of PD-1 function by cis -PD-L1/CD80 interactions is required for optimal T cell responses
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Sparing T cells from inhibition Programmed cell death 1 (PD-1) is an inhibitory receptor that normally keeps T cell immune responses in check. Immunotherapy targeting PD-1 has proven successful for certain types of cancer, but it remains unclear how PD-1 is regulated. Sugiura et al. found that a costimulatory molecule, CD80, can restrict PD-1 function during the activation of T lymphocytes. Binding of CD80 to the PD-1 ligand PD-L1 in cis on primary activated dendritic cells interfered with the ability of PD-L1 to access PD-1 on T cells, which would otherwise have inhibited T cell activation. Functional insights into PD-L1–CD80 interactions may explain the outcomes of anti–PD-1 and anti–PD-L1 cancer therapy. Science , this issue p. 558
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, PD‐L1 can interact in cis with Cluster of differentiation 80 (CD80) to PD‐1 [276, 277, 278], which may disturb the PD‐L1 and PD‐1 interaction and the CTLA4 and CD80 interaction and also maintain the flexibility of CD80 to trigger the signaling of CD28 [277, 279].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [278]
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Cited by
Items 301–393 of 393
Tomioka, N., Hatanaka, K. C., Okuyama, D., Watanabe, K., YAMAMOTO, M., Maeda, H., Tachikawa, H., Kuwahara, S., Shimizu, A., Suzuki, H., et al. (2023) · Breast Cancer · doi:10.1007/s12282-023-01442-9 · Cited by 3
Iwamoto, T., Nozaki, Y., Tsuji, S., Hukusima, H., Yamauchi, R., Nakanishi, R., Nagahama, S., Sunaga, K., Yamaoka, S., Suda, T., et al. (2020) · Kanzo · doi:10.2957/kanzo.61.572 · Cited by 3
Two CTLA-4 ligands, separate pHates
Humphries, P. A., & Lo, W. (2022) · Nature Immunology · doi:10.1038/s41590-022-01296-x · Cited by 3
Jiang, C., Sun, C., Wang, X., Ma, S., Jia, W., & Zhang, D. (2024) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-024-01026-9 · Cited by 2
Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy
Luo, J., Zhang, Q., Wang, S., Zheng, L., Liu, J., Zhang, Y., Wang, Y., Wang, R., Xiao, Z., & Li, Z. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096281451240306062101 · Cited by 2
Ligand-receptor interactions induce and mediate regulatory functions of BATF3 + B cells
Yan, H. M., Wang, R., Viswanadhapalli, S., Cervantes, C., He, F., Wu, S., Khosh, A., Luo, W., Wang, J., Fernandez, M. J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx9917 · Cited by 2
Mitchell, J. T., Stapleton, O., Krishnan, K., Nagaraj, S., Lvovs, D., Cherry, C., Poissonnier, A., Horton, W. R., Adey, A., Rao, V., et al. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag089 · Cited by 5
Yang, Y., Qiao, S., Sun, D., Zhang, Z., Zhao, Y., Zhan, J., Huang, Y., Zhao, H., Yang, Y., Wu, K., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02793-4 · Cited by 3
Aptamer-Coupled Droplet CRISPR/Cas12a Enables Ultrasensitive sPD-L1 Detection
Wu, Y.-S., Jin, R., Lei, T., Liu, J., Chang, Y., Zhang, Z. D., Li, J., & Liu, M. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c00779 · Cited by 2
Yang, Z., Han, H., Zhao, Z., Ding, L., Xu, X., Ma, M., Luo, M., & Tang, W. (2026) · ACS Nano · doi:10.1021/acsnano.6c03725 · Cited by 2
Mu, M., Zhang, M., Gong, Y., Guo, K., Liu, H., Zhang, Z., Jiang, T., Zhou, H., Fan, Q., Jia, D., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.158139 · Cited by 2
Regulate PD-L1's membrane orientation thermodynamics with hydrophobic nanoparticles
Lin, X., & Lin, X. (2024) · Biomaterials Science · doi:10.1039/d4bm01469c · Cited by 2
Cryolysate of Tumor Cells: From Technology of Its Obtaining Up to Creation of Anti-Cancer Vaccines
Goltsev, А., Gaevska, Y., Дубрава, Т. Г., Bondarovych, M. O., Lutsenko, O. D., & Ostankov, M. V. (2024) · Problems of Cryobiology and Cryomedicine · doi:10.15407/cryo34.03.226 · Cited by 2
Herbaux, C., Bachy, E., Bouabdallah, R., Guidez, S., Casasnovas, O., Feugier, P., Damaj, G. L., Tilly, H., Ysebaert, L., Gouill, S. L., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20109 · Cited by 4
CD80-Mediated T-Cell Suppression by Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma
Xiao, M., Qiu, L., Gao, Q., Li, R., Wang, J., Feng, Y., Li, X., & Ge, X. (2026) · Cells · doi:10.3390/cells15030266 · Cited by 2
Sammons, S. L., McNamara, M. A., Salama, A. K. S., & Crawford, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_12 · Cited by 2
Zhang, T., Chen, M. L., Liu, X. Y., He, H., Xu, Y., Tian, Z., Xing, H., Tang, K. J., Rao, Q., Wang, M., et al. (2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.05.005 · Cited by 2
del Rio, M., Pérez‐Simón, J. A., & Rodríguez-Barbosa, J.-I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887348 · Cited by 2
Evolving Understanding of T-cell Cosignaling Pathways
Yang, Y., Li, Y., & Xu, F. (2022) · Transplantation · doi:10.1097/tp.0000000000004181 · Cited by 2
Generation and quality control of mature monocyte-derived dendritic cells for immunotherapy
Datsi, A., Falkowski, L., & Sorg, R. V. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.05.007 · Cited by 2
Zheng, X., Tang, W., Tang, Q., Wu, Q., & Shan, J. (2025) · Immunobiology · doi:10.1016/j.imbio.2025.153133 · Cited by 1
Alam, S. S. M., Mir, S. A., Samanta, A., Ali, S., & Hoque, M. (2026) · ChemistrySelect · doi:10.1002/slct.202505365 · Cited by 1
Wang, Y., Song, Y., Xie, Y., Zhang, J., Liu, J., Wang, W., Xu, Y., Wu, W., Zhou, W., Jin, Q., et al. (2026) · Advanced Science · doi:10.1002/advs.202520420 · Cited by 2
Mechanical force regulates the inhibitory function of PD-1
Chen, H., Zhang, Y., Cui, L., Fan, J., Zhu, H., Wu, S., Zhou, H., Zhang, Y., Song, G., Jiang, N. J., et al. (2026) · EMBO Reports · doi:10.1038/s44319-026-00715-6 · Cited by 2
T cell exhaustion: next-generation target of autoimmune diseases?
Ouyang, Y., Luo, M., Li, K., Chen, K., Wen, Z., Zhou, Q., Shi, G., Xu, S., Luo, Z., & Yang, H. U. I. (2026) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiag052 · Cited by 1
Vounckx, M., Dirven, I., Bertels, C., Schwarze, J. K., Geeraerts, X., Tuyaerts, S., Boisson, A., Willard-Gallo, K. E., & Neyns, B. (2026) · Vaccines · doi:10.3390/vaccines14050402 · Cited by 2
Lima, C. M. S. P. R., Yothers, G., George, T. J., Höchster, H. S., Sanoff, H. K., Cohen, D. J., Guthrie, K. A., Jacobs, S. A., Saeed, A., Kopetz, S., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-03052 · Cited by 4
Huang, Y., Zhang, J., Tu, K., Ye, W., Zou, S., Tang, Z., & Zeng, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1881958 · Cited by 1
Maru, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-1757-7_16 · Cited by 1
Immune-checkpoint kinetics for T cells in anti-MDA5 positive interstitial lung disease
Suzuki, K., Yanagihara, T., Matsumoto, K., Chong, S. G., Ando, H., Ide, M., Arimura‐Omori, M., Hata, K., & Hamada, N. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa412 · Cited by 1
De novo priming: driver of immunotherapy responses or epiphenomenon?
Young, A. L., Lorimer, T., Al-Khalidi, S., & Roberts, E. W. (2023) · Essays in Biochemistry · doi:10.1042/ebc20220244 · Cited by 2
Colorectal cancer subtyping and prognostic model construction based on interleukin-related genes
Song, J., Chen, J., Chen, Y., Wang, Y., Zheng, L., Yu, H., & Chen, C. (2023) · Physiological Genomics · doi:10.1152/physiolgenomics.00099.2023 · Cited by 1
Wu, Y., Liang, X., Sun, Y., Ning, J., Dai, Y., Jin, S., Xu, Y., Chen, S., & Pan, L. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200827 · Cited by 1
Adem, E., Yizengaw, E., Mulaw, T., Nibret, E., Müller, I., Takele, Y., & Kropf, P. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012417 · Cited by 1
Jaramillo, C. A. C. (2020) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-b-000477547 · Cited by 2
Kim, S., Toth, P. D., Wang, W. J., Seiradake, E., Shi, X., & Wang, B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.31.667925 · Cited by 2
Study of the function of dendritic cells in skin type 2 immune response
Marschall, P. (2019) · theses.fr (ABES) · doi:10.70675/18263075z5790z4c30za432z23a59edcd8cb · Cited by 2
Dendritic Cells and Their Roles in Anti-Tumour Immunity
Pang, E. S., Macri, C., Patton, T., Bafit, M., & O’Keeffe, M. A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91692
Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer
Zhao, X. (2020) · University of Minnesota Digital Conservancy (University of Minnesota)
Immune Targets in Colorectal Cancer
Dariya, B., & Nagaraju, G. P. (2020) · Diagnostics and therapeutic advances in GI malignancies · doi:10.1007/978-981-15-6487-1_12
The Divergent Role of Co-receptors and Cytokines in the Immune Response to Cancer and Self
Tucker, C. (2020) · University of Minnesota Digital Conservancy (University of Minnesota)
Immunological effects of photodynamic therapy
Lobo, C. S. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Sonnenburg, A. (2021) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-31019
Zhao, W., Liang, Y., & Wang, L. (2021) · Aging Pathobiology and Therapeutics · doi:10.31491/apt.2021.12.071
Co-stimulatory molecules decide T cell fate through regulations of their invigoration and impairmentPreprint
Ichikawa, K., & Ichikawa, K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.21.508809
The Role of Soluble Immune Checkpoints in Cancer Immunotherapy
Huntington, K. E., & El‐Deiry, W. S. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_164-1 · Cited by 1
Yin, W., Xie, D., Tang, G., Ren, C., & Jiang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3505524/v1
Elucidating molecular and cellular mechanisms of singularity phenomena in immunology
Okazaki, T., & Katakai, T. (2024) · Biophysics and Physicobiology · doi:10.2142/biophysico.bppb-v21.s007
Self-citationBarthout, E. (2022) · theses.fr (ABES) · doi:10.70675/487f8a2fz9ca1z4c32za6dcz93bc59783a4b
Joseph, E. L. M. (2019) · theses.fr (ABES) · doi:10.70675/bba1a27bz36bdz488cza60azf58fa2e47702
Nishi, W., Wakamatsu, E., Machiyama, H., Matsushima, R., Yoshida, Y., Nishikawa, T., Toyota, H., Furuhata, M., Nishijima, H., Takeuchi, A., et al. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-9781-7_13
Inflammatory Response and Immune Disorder in Rheumatic and Musculoskeletal Diseases
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5248-3
Macrophage‐Tased Dual‐Phase T Cell Immunomodulation to Combat Transplant Rejection
Wang, W., Gao, T., Wang, Y., Wang, R., He, M., Wang, L., Zhou, W., Ding, M., Song, Y., Ji, X., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403591
A multifunctional T-cell engager containing CD80 enhances prostate cancer treatment
Nie, D., Jiang, Y., Li, H., Zhang, K., Li, Z., Lü, T., Li, Y., Han, D., Shi, C., Xing, N., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04121-0
Anti-angiogenesis enhances the tumor immunotherapeutical effect of recombinant CD80 fusion protein
Wang, S., Huang, L., Zhang, X., Fan, J., Zou, J., Hong, W., Tuerdi, A., Zhu, Y. Z., Hu, P., & Li, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146350
Wing, J. B., & Sakaguchi, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00276-3
Lnk/Sh2b3 regulates initiation and severity of autoimmune insulitis and contributes to diabetes risk
Tenno, M., & Τακακι, S. (2025) · Life Science Alliance · doi:10.26508/lsa.202503332
The Role of Soluble Immune Checkpoints in Cancer Immunotherapy
Huntington, K. E., & El‐Deiry, W. S. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_164
Characterizing the PD-L1:CMTM6 Interaction
Chang, I. (2023) · eScholarship (California Digital Library)
Danelon, V., Garrett-Thomson, S. C., Morano, N. C., Constanza, R., Kermani, P., Smith, R. S., Almo, S. C., Lee, F. S., & Hempstead, B. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.30.697078
PD-L1 is an intrinsic switch for natural killer cell-mediated, TRAIL-dependent antiviral function
Frank, K., Sharma, H., Motakis, E., Nourbakhsh, N., Abeynaike, S. A., Huynh, T. R., Jones, C. A., Johnson, S. K., Tompkins, S. M., & Paust, S. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116939
Käyhty, P., Nieminen, T., Hyvönen, A., Albers-Skirdenko, J., Airenne, T. T., Johnson, M. S., Lesch, H. P., Ylä-Herttuala, S., & Airenne, K. J. (2026) · Human Gene Therapy · doi:10.1177/10430342261422764
Role of immunotherapy and immune checkpoint inhibitors in cancer therapy
Singh, S., Sharma, N., Behl, T., Arora, S., Kumar, P., Srivastava, S., & Kishore, L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31592-3.00015-7
PD-L1 cell-intrinsic signals limit immune activation during cutaneous vaccinia virus infection
Kantheti, U., Shirley, J. L., Fry, L. G., Qvale, A. M., Olivas-Corral, J. G., Vankamamidi, S. E., & Tamburini, B. A. J. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkaf368
Ito, F., Kobayashi, K., Hayashi, G., Kamijo, S., & Fujita, T. (2026) · IJU Case Reports · doi:10.1002/iju5.70160
Han, G. M., Lim, C. S., & Lee, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.30.715283 · Cited by 1
Ruggiu, M. (2023) · theses.fr (ABES) · doi:10.70675/de84e089z4e46z475dz8d12z25950ab6f427
Characterization of regulatory T cells populations in breast cancers
Fattori, S. (2023) · theses.fr (ABES) · doi:10.70675/1c177425zb8daz422fza46dz677464719c36
PD-1 blockade enhances T cell activation by reorchestrating CD28 and CTLA4 ligand interactionsPreprint
Eun, G. S., Boyd, J., Au, V., Garcia, A., Čemerski, S., Dovedi, S. J., Pollizzi, K. N., Dustin, M. L., & Varma, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.12.718055
The dual role of peritoneal cavity B cells in the activation of antitumor T cells
Mochizuki, T., Tanaka, Y., Ide, R., & Ohdan, H. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag058
ILC2s and their immune checkpoints in the antitumor response
Ciancaglini, C., Santopolo, S., Vacca, P., Moretta, L., & Quatrini, L. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014183
Zolotar, A., Wiebe, D. S., Petrosyants, A., Shpak, B., Khotkina, N., Beliaeva, V., Ivleva, E., Balabanian, L., Chelushkin, M., Dyikanov, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.28.721082
Nakashima, I., Saito, S., Zhao, J., Tanaka, M., Akahoshi, E., Hasegawa, A., Ishihara‐Sugano, M., Yagyu, S., & NAKAZAWA, Y. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201234
Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies
Ge, Q., Yu, L., Lu, J., Anwaier, A., Xiao, X., Chen, Y., Ye, D., Zhang, H., Xu, W., & Dai, W. (2026) · MedComm · doi:10.1002/mco2.70771 · Cited by 1
Spatial Omics Revisits Cancer Immunity and Reshapes Immunotherapy
Chu, H., Shi, Y., Tian, Z., Ma, J. Y., Bian, X. W., & ZHU, B. (2026) · Fundamental Research · doi:10.1016/j.fmre.2026.04.033
Yang, Y., Peng, J., Wei, J., Qin, J., Yang, J., Liu, M., & Wang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04722-6
PD-L1 deletion or blockade intrinsically reduces macrophage CD80 levels
Waddell, T. Q. A., Dong, H., Roh‐Johnson, M., & Lancaster, J. N. (2026) · Frontiers in Oncology · doi:10.64898/2026.06.23.734016
Chandran, S., Tang, Q., Leung, J., Armstrong, B., Friedewald, J. J., Kirk, A. D., Laszik, Z. G., Goldstein, J., Morsheimer, M. M., & Vincenti, F. G. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.07.016
Zhao, S., Shi, T., Tian, T., Zhang, F., Zhang, Z., Xu, H., Zhou, Y., Li, Z., Qin, Z., Xu, P., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2604171123
Li, S., Huang, J., Fang, R., Zhang, M., Jin, Y., Zhu, Y., & Ma, C. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152541
Engineered human iPSC-derived dendritic cells dressed with tumor MHC complexes as a cancer vaccine
Xu, H., Kamei, C., Gökbuget, D., DU, J. N., Barrero, M., Wang, L., Iwamoto, Y., Soriano, J. M., Godding, K., Wang, B., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.07.017
CD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis
Blagov, A. V., Vatlin, A. A., Borodko, D. D., & Maksaeva, A. O. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188215
Kitahara, Y., Inui, N., Koyauchi, T., Asada, K., Nishimoto, K., Matsuura, S., Hashimoto, D., Matsui, T., Fujii, M., Inami, N., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag377
NKG2D overexpression potentiates CAR-T cells through costimulation by tumor NKG2D ligands
Li, J., Han, L., Zhu, Q., Liu, N., Ma, H., Wu, Z., Wang, Y., Lin, X., Wei, J., & Han, W. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103116
Roy, N. K., Pal, S., Dar, H. Y., Patil, S., Weitzmann, M. N., & Pacifici, R. (2026) · JCI Insight · doi:10.1172/jci.insight.207567
Xiao, Q., Jing, Z., Qiu, Y., Tao, T., Yang, J., Xiao, Y., Rao, L., Zheng, M., Yi, X., Zhang, L., et al. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c05180
Li, S., Barden, M., Pan, H., Harrer, D. C., Kaljanac, M., Bezler, V., Ertelt, M., Schoeder, C., Chen, T.-Y., & Abken, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1906848
Metadata
- Authors
- Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T.
- Affiliations
- Institute of Advanced Medical Sciences, Tokushima University (JP)
- Corresponding author
- Sugiura, Daisuke
- Maruhashi, Takumi
- Okazaki, Il-mi
- Shimizu, Kenji
- Maeda, Takeo K.
- Okazaki, Taku
- ORCID
- Venue
- Science
- Published
- 2019-05-10
- Volume
- 364
- Issue
- 6440
- Pages
- 558-566
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2936616584
- Cited by
- 386
- References
- 40
- Citations by year
- 2026: 44 · 2025: 40 · 2024: 61 · 2023: 49 · 2022: 52 · 2021: 63 · 2020: 53 · 2019: 23
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP18am0301007)
- Japan Society for the Promotion of Science (JP18H05417)
- Core Research for Evolutional Science and Technology, Japan Science and Technology Agency
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, CD80, T cell activation, T cell suppression, costimulation, dendritic cells, anti-PD-1 therapy, PD-L1 blockade, cancer immunotherapy, immune checkpoint regulation
- MeSH terms
- Animals, Dendritic Cells, Humans, Immunotherapy, Lymphocyte Activation, Mice, Mutant Strains, Neoplasms, Protein Binding, T-Lymphocytes, Autoimmunity, CD28 Antigens, B7-1 Antigen, Mice, Gene Knock-In Techniques, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.